Author

Li Zhou

Observed names: L. Zhou, Li Zhou, PhD

Institution: Curis (United States)

Observed institution: Curis (United States)

ORCID: 0009-0001-0105-8111

Observed ORCID: 0009-0001-0105-8111

OpenAlex ID: A5081441772

Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome.

2022 · Guillermo Garcia-Manero, Eric S. Winer, et al. · Journal of Clinical Oncology · 42

S129: Takeaim Leukemia- a Phase 1/2a Study of the Irak4 Inhibitor Emavusertib (ca-4948) as Monotherapy or in Combination With Azacitidine or Venetoclax in Relapsed/refractory Aml or Mds

2022 · G. Garcia-Manero, E. S. Winer, et al. · HemaSphere · 26

Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.

2022 · Erel Joffe, Grzegorz S. Nowakowski, et al. · Journal of Clinical Oncology · 4

P1121: Takeaim Lymphoma- an Open-label, Dose Escalation and Expansion Trial of Emavusertib (ca-4948) in Combination With Ibrutinib in Patients With Relapsed or Refractory Hematologic Malignancies

2022 · E. Joffe, G. Nowakowski, et al. · HemaSphere · 3

Preliminary pharmacokinetic and MRD results from AML patients treated with 7- and 14-day dosing schedule of emavusertib added to combination therapy with azacitidine and venetoclax

2025 · Cristina Papayannidis, Ulf Schnetzke, et al. · Blood · 1

Ctni-63. Preliminary Safety and Efficacy of Emavusertib (ca-4948) in Combination With Ibrutinib in Relapsed/refractory Primary Central Nervous System Lymphoma Patients

2025 · Lakshmi Nayak, MD, Anna Dabrowska-Iwanicka, MD, et al. · Neuro-Oncology

Works count: 6

Citation count: 76

H-index: 3

I10-index: 2